The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry

Empowering mental health professionals with peer-reviewed psychiatric research and insights

Back to top Open menu arrow
Current Issue Archives Authors Reviewers

Just Published

JCP
Racial Disparities in Mood Stabilizer Prescribing in Mania
Original Research

February 3, 2025

Significant disparities in prescription rates of valproic acid and lithium were observed, with Black patients more likely to receive valproic acid and less likely to receive lithium compared to…
, , , et al
JCP
Opioid Use Disorder in Sexually and Gender Diverse Populations: Can We Do Better?
Letter to the Editor

February 3, 2025

The authors respond to a recent JCP article by McDowell and colleagues.
, ,
JCP
Relationship Between Trauma, PTSD, and Schizophrenia
ASCP Corner

January 29, 2025

The authors summarize the clinical relevance of trauma and PTSD in patients with schizophrenia and examine assessment and treatment options of trauma and related conditions to consider when treating…
,

Vol 85 • 2024 • Number 4

Read the Current Issue

Meta-Analysis

Changes in Cognition in Patients With Schizophrenia

Systematic Review

Diagnostic Assessment via Telehealth vs Face-to-Face

Original Research

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Original Research

Bridge Symptoms Between Borderline Personality and PTSD

Original Research

Gepirone-ER and Sexual Function in Patients with MDD

Original Research

Medication Use and Lines of Treatment in Patients With Insomnia Disorder
View current Issue

Explore Special Sections

View all topics
Focus on Psychosis Focus on Geriatric Psychiatry Focus on Women’s Mental Health Focus on Suicide Early Career Psychiatrists Focus on Psychotherapy

Original Research

JCP
ECT for Psychotic vs Nonpsychotic Depression
Original Research

January 29, 2025

Patients with major depression with psychotic features had higher response rates to ECT than those without psychotic features and similar rates of adverse cognitive effects. After adjustment for confounders,…
, , , et al
JCP
Esketamine Nasal Spray vs Quetiapine ER in Treatment-Resistant Depression
Original Research

January 27, 2025

Esketamine was associated with significantly larger improvements in work productivity loss and related costs compared to quetiapine, suggesting greater benefits from patient well-being and employer perspectives.
, , , et al
JCP
Psychological Challenges of Adults with SMI during the COVID-19 Pandemic
Original Research

January 22, 2025

Adults with SMI diagnosed with COVID-19 and those who sheltered in place during lockdown experienced more severe psychological distress compared to those not diagnosed with COVID-19.
, , , et al

Review Articles

JCP
Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia
Review Article

August 21, 2024

Patients with schizophrenia and cognitive impairment had a 100% increase in relapse-related hospitalizations and ER visits versus patients with no (or only mild) cognitive impairment.
JCP
Cognitive Effects of ECT in Schizophrenia: A Review
Review Article

June 5, 2024

ECT was not associated with any significant cognitive deficits in people with treatment-resistant schizophrenia across global cognition, attention, language, visuospatial function, and executive function domains. The majority of studies…
JCP
Interpersonal Psychotherapy for PTSD: A Critical Review
Review Article

May 29, 2024

This critical review will give clinicians confidence in considering IPT as an alternative to exposure treatments for posttraumatic stress disorder.
JCP
Omega-3 PUFA Supplements for ADHD
Meta-Analysis

August 30, 2023

Although omega-3 polyunsaturated fatty acids (PUFAs) may not improve core symptoms of attention-deficit/hyperactivity disorder, longer-term PUFA supplementation may have potential benefits.
, , , et al
JCP
Mechanisms of Treatment of Bipolar Disorder and Borderline Personality Disorder: Brain Imaging Research
Meta-Analysis

March 27, 2023

Different brain regions were changed with psychotherapy versus medication. The findings may help with predicting treatment efficacy and identifying treatment biomarkers in these disorders.
, , , et al
JCP
Antipsychotic Dose and Weight Gain
Meta-Analysis

February 8, 2023

Although effects on weight gain have been explored for several antipsychotics, the role of dose in producing these effects has not been widely studied. This meta-analysis examined the association…
, , , et al

Read articles from ASCP Corner

ASCP Corner

Letters to the Editor

JCP
Mental Health Assessment and Psychosocial Intervention in Maternal-Fetal Interventions
Letter to the Editor

November 18, 2024

In discussing a recent JCP letter to the editor, Akerson et al recommend that centers for fetal diagnosis and treatment include a social worker who can provide psychosocial assessment,…
, , , et al
JCP
Clarification Regarding the Psychiatrist’s Role—Reply to Akerson et al
Letter to the Editor

November 18, 2024

The authors respond to a letter by Akerson et al.
, , , et al
JCP
Detecting Misuse of Prescription Opioids
Letter to the Editor

October 21, 2024

The authors discuss the difficulty in screening for opioid misuse and the need for clinicians to gain confidence in initiating difficult discussions with patients on long-term opioid treatment.
, ,
JCP
Mental Health Assessments for Fetal Interventions
Letter to the Editor

June 24, 2024

The authors offer guidance and raise awareness about the intersection of maternal mental health and fetal interventions.
, ,
JCP
Why Ask Patients to Cut Into Quarters 10 mg THC Gummies From a Dispensary When 2.5 mg THC Is Available by Prescription?
Letter to the Editor

June 5, 2024

The authors discuss a study by Sawicki et al of dementia patients for whom 2.5 mg of THC was recommended for neuropsychiatric symptoms.
,
JCP
THC Edible Gummies for Behavioral Symptoms of Dementia: Reply to Goldman and Markov
Letter to the Editor

June 5, 2024

The authors reply to Goldman and Markov’s comments on their recent study of dispensary-obtained THC for dementia.
,

Commentaries

JCP
Evolving Care and Research Priorities in ADHD
Commentary

December 23, 2024

Surman and Wilens discuss two recent JCP articles highlighting that how ADHD manifests can be heavily influenced by context, as well as individual vulnerabilities and strengths.
,
JCP
The Opioid Industry's Legacy: A Generation of Prescribed Suffering
Commentary

December 18, 2024

The authors discuss the influential and far-reaching effects of messaging from the opioid industry on the opioid use epidemic.
,
JCP
SUD Programs for Transgender and Gender Diverse Patients
Commentary

November 11, 2024

The authors discuss responsiveness of transgender and gender diverse patients to SUD treatment at different care levels (eg, outpatient, residential, inpatient), as well as how to reduce stressors and…
,
JCP
Clinical Implications of Adult ADHD: What New Data Tell Us
Commentary

October 10, 2024

The authors discuss striking new findings from the Morbidity and Mortality Weekly Report on the burden of adult ADHD, demonstrating the need for the upcoming APSARD Adult ADHD Guidelines.
,
JCP
Reproductive Pharmacovigilance and Best Practices
Commentary

August 26, 2024

Dr Freeman discusses a recent study by Pacilio et al that characterized real world practices around ketamine treatment and pregnancy testing, consent processes, and contraception use. She emphasizes the…
JCP
Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine
Commentary

August 21, 2024

Dr Rosenbaum comments on the challenge of evaluating trials of treatments whose effects are unmistakable, and how this dilemma may be addressed.

More JCP Articles

JCP
A Collaborative Endeavor
Editorial

January 29, 2025

JCP’s Editor in Chief thanks reviewers, editorial board members, and editors for their contributions to the journal over the past year.
JCP
Ketamine vs ECT in the Management of Treatment-Resistant Depression: Do We Need More Data?
Brief Report

January 27, 2025

Data suggest the difference between ketamine and ECT in efficacy for treatment-resistant depression may be smaller than previously thought.
, , , et al
JCP
Suicides by Sodium Nitrite Reported to US Poison Centers
Brief Report

January 22, 2025

During 2020-2023, the number of sodium nitrate exposure cases peaked at 39 in 2022, with a drop to 29 in 2023. Case fatality was 41.5%.
,
JCP
Sulforaphane Added to Antipsychotics for Negative Symptoms of Schizophrenia
Original Research

January 20, 2025

Add-on high dose sulforaphane may reduce negative symptoms in patients with schizophrenia, although the clinical significance of this reduction needs further evaluation.
, , , et al
JCP
Synopsis of the VA/DOD Clinical Practice Guideline for Management of Bipolar Disorder
Consensus Statement

January 13, 2025

This synopsis focuses on clinically relevant recommendations related to identification and management of bipolar disorder, including the acute and maintenance phases of illness.
, , , et al
JCP
BI 1358894 in Borderline Personality Disorder
Original Research

January 13, 2025

Although the primary endpoint was not met, BI 1358894 was well-tolerated with no increase in self-harm or suicidality.
, , , et al
JCP
Inpatient Treatment of Suicidality
Systematic Review

January 8, 2025

Effective, rapid treatments that target suicidality in psychiatric inpatients are scarce in the existing literature and in clinical practice, underscoring the need for studies to identify and validate these…
, , , et al
JCP
Cardiovascular Risk Factors and Second Generation Antipsychotics
Original Research

January 8, 2025

Despite well-documented cardiovascular disease (CVD) morbidity and mortality, CVD risks among people with severe mental illness who use antipsychotics are common and frequently untreated.
, , , et al
JCP
Cannabis Use During Pregnancy and Neuropsychiatric Adverse Outcomes in Children and Young Adults
Clinical and Practical Psychopharmacology

January 6, 2025

Current research suggests that prenatal cannabis exposure is linked to many adverse outcomes, including psychosis proneness, psychotic-like experiences, internalizing and externalizing problems, attention problems, thought-related problems, social problems, impaired…
JCP
IV Hydroxyzine vs Haloperidol for Delirium
Original Research

January 6, 2025

Hydroxyzine showed a significantly higher rate of delirium improvement than haloperidol, with no significant difference in the time to improvement.
, , , et al
JCP
Olanzapine/Samidorphan Effects on Weight Gain
Original Research

January 2, 2025

Treatment with a combination of olanzapine and samidorphan was associated with less weight gain and reduced risk of reaching ≥7% or ≥10% gain in body weight versus olanzapine over…
, , , et al
JCP
Substance and Opioid Use Disorders Among IBD Hospitalizations
Original Research

January 2, 2025

A higher prevalence of SUD and opioid use disorder was found among hospitalizations for inflammatory bowel disease, and these elevated prevalences were linked to distinct demographic, socioeconomic, and geographic…
, , , et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe